Taipei, Taiwan

Che-Ming Teng

USPTO Granted Patents = 41 


 

Average Co-Inventor Count = 4.9

ph-index = 8

Forward Citations = 272(Granted Patents)


Location History:

  • Taipei 106, TW (2003)
  • Taipei, TW (1992 - 2022)

Company Filing History:

goldMedal9 out of 544 
 
National Science Council
 patents
silverMedal6 out of 16 
 
Yung Shin Pharmaceutical Ind. Co., Ltd.
 patents
bronzeMedal6 out of 99 
 
China Medical University
 patents
46 out of 133 
 
Taipei Medical University
 patents
54 out of 14 
 
Yung Shin Pharm. Ind. Co., Ltd.
 patents
64 out of 1,712 
 
National Taiwan University
 patents
72 out of 4 
 
Carlsbad Technology, Inc.
 patents
82 out of 827 
 
The Ohio State University
 patents
92 out of 1,269 
 
University of North Carolina at Chapel Hill
 patents
101 out of 1 
 
Angiorx Corporation
 patent
111 out of 53 
 
National Science Council of Republic of China
 patents
121 out of 18 
 
China Medical University Hospital
 patents
131 out of 1 
 
Yung Shin Pharmaceuticals Industrial Co., Ltd
 patent
141 out of 16 
 
Medical and Pharmaceutical Industry Technology and Development Center
 patents
151 out of 9,138 
 
Industrial Technology Research Institute
 patents
161 out of 2 
 
National Science Council of Taiwan
 patents
171 out of 832,680 
Other
 patents
where one patent can have more than one assignee

Years Active: 1992-2022

where 'Filed Patents' based on already Granted Patents

41 patents (USPTO):

Title: Che-Ming Teng: A Pioneer in Pharmaceutical Innovations

Introduction: Che-Ming Teng, based in Taipei, Taiwan, is a prominent inventor with an impressive portfolio of 41 patents. His work primarily focuses on innovative pharmaceutical compounds aimed at treating critical medical conditions. With a strong academic and professional background, Teng has made significant contributions to the fields of biochemistry and medicinal chemistry.

Latest Patents: Among his latest patents, Teng has developed heat shock protein 90 inhibitors. This invention relates to aromatic compounds that help in treating medical conditions associated with Heat Shock Protein-90 (HSP90), particularly cancer. The compounds of formula (I) and their pharmaceutical compositions represent a notable advancement in cancer treatment methodologies. Additionally, Teng has patented hydroxamic acid compounds that act as histone deacetylase 6 inhibitors. This patent outlines the pharmaceutical composition containing such compounds and elaborates on methods for treating conditions linked to histone deacetylase 6 dysregulation.

Career Highlights: Throughout his career, Che-Ming Teng has been affiliated with esteemed institutions such as the National Science Council and Yung Shin Pharmaceutical Industries Co., Ltd. His work has been instrumental in fostering innovation in drug discovery and therapeutic development, further establishing him as a leading figure in his field.

Collaborations: Collaborating with talented individuals, Teng has worked alongside coworkers such as Sheng-Chu Kuo and Shiow-Lin Pan. These collaborations have enhanced his research output and fostered the development of groundbreaking innovations in pharmaceuticals.

Conclusion: Che-Ming Teng's contributions to pharmaceutical innovations and his extensive patent portfolio underscore his vital role in advancing medical research. His latest inventions in the realm of therapeutic compounds illustrate the potential to significantly impact treatment options for patients with challenging medical conditions. As his career progresses, Teng will undoubtedly continue to play a crucial role in the development of innovative therapies in the pharmaceutical industry.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…